This study is in progress, not accepting new patients

Prevention of Colorectal Cancer Through Multiomics Blood Testing

a study on Colon Cancer Colorectal Cancer Rectal Cancer Colon Disease Colon Lesion Colon Polyps Polyp Adenoma Rectal Diseases Gastrointestinal Cancer Colorectal Tumor

Summary

Eligibility
for people ages 45-85 (full criteria)
Healthy Volunteers
healthy people welcome
Location
at UCLA UCSD UCSF
Dates
study started
completion around

Description

Summary

The PREEMPT CRC study is a prospective multi-center observational study to validate a blood-based test for the early detection of colorectal cancer by collecting blood samples from average-risk participants who will undergo a routine screening colonoscopy.

Details

Freenome is using a type of artificial intelligence, called machine learning, to identify patterns of cell-free biomarkers in blood to detect cancer early. The purpose of this prospective multi-center observational study is to validate a blood-based test for the detection of colorectal cancer by collecting blood samples from average-risk participants who will undergo a routine screening colonoscopy.

Keywords

Colon Cancer, Rectal Cancer, Colon Neoplasm, Colon Diseases, Colon Lesion, Colon Polyp, Colorectal Cancer, Polyp, Adenoma, Rectal Diseases, Gastrointestinal Tract Cancers, Artificial Intelligence, Liquid Biopsy, Blood Test Cancer, Cancer Diagnostic, Genomics, Genomics Test, CRC, Cancer Screening, Cancer Early Detection Test, Screening, Colonoscopy, Machine Learning, Freenome Test, Colorectal Cancer (CRC), Colorectal Cancer Screening, Colorectal Neoplasms, Colonic Neoplasms, Gastrointestinal Neoplasms, Colonic Diseases, Polyps

Eligibility

You can join if…

Open to people ages 45-85

  1. 45-85 years of age
  2. Willing to undergo a standard-of-care screening colonoscopy
  3. Able and willing to provide a blood sample
  4. Able and willing to sign informed consent

You CAN'T join if...

  1. Known hereditary gastrointestinal cancer syndrome (for example, hereditary non-polyposis CRC syndrome (HNPCC) or Lynch syndrome, or familial adenomatous polyposis (FAP)
  2. Personal history 2.1 CRC or colorectal adenoma 2.2 Inflammatory bowel disease (IBD), including chronic ulcerative colitis (CUC) and crohn's disease (CD) 2.3 Colonoscopy in the 9 years preceding enrollment 2.4 Stool DNA testing in the 2 years preceding enrollment 2.5 Symptoms of lower gastrointestinal tract disease warranting colonoscopic evaluation
  3. A medical condition which, in the opinion of the Investigator, should preclude enrollment in the study
  4. Participated or currently participating in a clinical research study in which an experimental medication has been administered during the 60 days up to and including the date of providing informed consent or may be administered through the time of the colonoscopy

Locations

  • UCLA Medical Center
    Los Angeles California 90095 United States
  • University of California San Diego Medical Center
    San Diego California 92103 United States
  • UCSF Mount Zion Medical Center
    San Francisco California 94115 United States
  • Digestive Health Associates
    Santa Monica California 90404 United States
  • Matrix Clinical Research
    Beverly Hills California 90212 United States
  • Science 37
    Los Angeles California 90094 United States
  • Paragon Rx Clinical - Santa Ana
    Santa Ana California 92703 United States
  • St. Joseph Heritage Healthcare
    Mission Viejo California 92691 United States
  • East Bay Center for Digestive Health
    Oakland California 94612 United States
  • Knowledge Research Center
    Orange California 92868 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Freenome Holdings Inc.
ID
NCT04369053
Study Type
Observational
Participants
Expecting 50000 study participants
Last Updated